Involvement of spinal tyrosine kinase in inflammatory and N-methyl-D-aspartate-induced hyperalgesia in ratsSATO, Eiru; TAKANO, Yoshito; KUNO, Yuichiro et al.European journal of pharmacology. 2003, Vol 468, Num 3, pp 191-198, issn 0014-2999, 8 p.Article

Third-Generation Tyrosine Kinase Inhibitors and BeyondQUINTAS-CARDAMA, Alfonso; KANTARJIAN, Hagop; CORTES, Jorge et al.Seminars in hematology. 2010, Vol 47, Num 4, pp 371-380, issn 0037-1963, 10 p.Article

Molecular Pathways: Resistance to Kinase Inhibitors and Implications for Therapeutic StrategiesLOVLY, Christine M; SHAW, Alice T.Clinical cancer research (Print). 2014, Vol 20, Num 9, pp 2249-2256, issn 1078-0432, 8 p.Article

Nilotinib: A Novel, Selective Tyrosine Kinase InhibitorBLAY, Jean-Yves; VON MEHREN, Margaret.Seminars in oncology. 2011, Vol 38, Num 2, issn 0093-7754, S3-S9, SUP1Article

NilotinibDEININGER, Michael W.Clinical cancer research. 2008, Vol 14, Num 13, pp 4027-4031, issn 1078-0432, 5 p.Article

The systemic mastocytosis-specific activating cKit mutation D816V can be inhibited by the tyrosine kinase inhibitor AMN107VON BUBNOFF, N; GORANTLA, S. H. P; KANCHA, R. K et al.Leukemia. 2005, Vol 19, Num 9, pp 1670-1671, issn 0887-6924, 2 p.Article

Tyrosine kinase inhibitor loaded PCL microspheres prepared by S/O/W technique using ethanol as pretreatment agentYANTING ZHANG; YAQIONG ZHANG; SHENGRONG GUO et al.International journal of pharmaceutics (Print). 2009, Vol 369, Num 1-2, pp 19-23, issn 0378-5173, 5 p.Article

Pazopanib: Clinical development of a potent anti-angiogenic drugSCHUTZ, Fabio A. B; CHOUEIRI, Toni K; STERNBERG, Cora N et al.Critical reviews in oncology/hematology. 2011, Vol 77, Num 3, pp 163-171, issn 1040-8428, 9 p.Article

Inhibitory effect of tyrphostin 47 on Shiga toxin-induced cell deathIKEDA, Masahiro; GUNJI, Yasuhiro; SONODA, Hiroko et al.European journal of pharmacology. 2006, Vol 546, Num 1-3, pp 36-39, issn 0014-2999, 4 p.Article

The Evolving Field of Tyrosine Kinase Inhibitors in the Treatment of Endocrine TumorsLEI YE; SANTARPIA, Libero; GAGEL, Robert F et al.Endocrine reviews. 2010, Vol 31, Num 4, pp 578-599, issn 0163-769X, 22 p.Article

Curcumin Disrupts the Mammalian Target of Rapamycin-Raptor ComplexBEEVERS, Christopher S; LONG CHEN; LEI LIU et al.Cancer research (Chicago, Ill.). 2009, Vol 69, Num 3, pp 1000-1008, issn 0008-5472, 9 p.Article

Nilotinib. CommentariesROSTI, Gianantonio; LE COUTRE, Philipp.Drugs (Basel). 2008, Vol 68, Num 4, pp 460-461, issn 0012-6667, 2 p.Article

Bumped Kinase Inhibitor 1294 Treats Established Toxoplasma gondii InfectionSTONE DOGGETT, J; OJO, Kayode K; FAN, Erkang et al.Antimicrobial agents and chemotherapy. 2014, Vol 58, Num 6, pp 3547-3549, issn 0066-4804, 3 p.Article

Thyroid effects of tyrosine kinase inhibitorsILLOUZ, Frédéric; BRAUN, Doreen; BRIET, Claire et al.European journal of endocrinology. 2014, Vol 171, Num 3, issn 0804-4643, R91-R99Article

Dosage plasrnatique des inhibiteurs de tyrosine kinaseBOUCHET, S; POULETTE, S; MOLIMARD, M et al.Correspondances en onco-hématologie. 2009, Vol 4, Num 4, pp 177-178, issn 1954-4820, 2 p.Article

Phase I, pharmacokinetic, and biological studies of TSU-68, a novel multiple receptor tyrosine kinase inhibitor, administered after meals with solid tumorsMURAKAMI, Haruyasu; UEDA, Yutaka; SHIMOYAMA, Tatsu et al.Cancer chemotherapy and pharmacology. 2011, Vol 67, Num 5, pp 1119-1128, issn 0344-5704, 10 p.Article

Hair depigmentation during chemotherapy with a class III/V receptor tyrosine kinase inhibitorROUTHOUSKA, Shannon; GILLIAM, Anita C; MIRMIRANI, Paradi et al.Archives of dermatology (1960). 2006, Vol 142, Num 11, pp 1477-1479, issn 0003-987X, 3 p.Article

Diagnosis and treatment of hypereosinophilic syndromesFLETCHER, Sarah; BAIN, Barbara.Current opinion in hematology. 2007, Vol 14, Num 1, pp 37-42, issn 1065-6251, 6 p.Article

Systemic therapy in neurofibromatosis type 2LIM, Stephanie Hui-Su; ARDERN-HOLMES, Simone; MCCOWAGE, Geoffrey et al.Cancer treatment reviews. 2014, Vol 40, Num 7, pp 857-861, issn 0305-7372, 5 p.Article

Immunohistochemical and molecular cytogenetic evaluation of potential targets for tyrosine kinase inhibitors in Langerhans cell histiocytosisCAPONETTI, Gabriel C; MIRANDA, Roberto N; ALTHOF, Pamela A et al.Human pathology. 2012, Vol 43, Num 12, pp 2223-2228, issn 0046-8177, 6 p.Article

Early prediction of success or failure of treatment with second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukemiaMILOJKOVIC, Dragana; NICHOLSON, Emma; KHORASHAD, Jamshid S et al.Haematologica (Roma). 2010, Vol 95, Num 2, pp 224-231, issn 0390-6078, 8 p.Article

A combinatorial in silico and cellular approach to identify a new class of compounds that target VEGFR2 receptor tyrosine kinase activity and angiogenesisKANKANALA, J; LATHAM, A. M; JOHNSON, A. P et al.British journal of pharmacology. 2012, Vol 166, Num 2, pp 737-748, issn 0007-1188, 12 p.Article

Analysis of outcomes in adolescents and young adults with chronic myelogenous leukemia treated with upfront tyrosine kinase inhibitor therapyPEMMARAJU, Naveen; KANTARJIAN, Hagop; SHAN, Jianqin et al.Haematologica (Roma). 2012, Vol 97, Num 7, pp 1029-1035, issn 0390-6078, 7 p.Article

MET inhibition in tumor cells by PHA665752 impairs homologous recombination repair of DNA double strand breaksMEDOVA, Michaela; AEBERSOLD, Daniel M; ZIMMER, Yitzhak et al.International journal of cancer (Print). 2012, Vol 130, Num 3, pp 728-734, issn 0020-7136, 7 p.Article

Estimations of the Increasing Prevalence and Plateau Prevalence of Chronic Myeloid Leukemia in the Era of Tyrosine Kinase Inhibitor TherapyXUELIN HUANG; CORTES, Jorge; KANTARJIAN, Hagop et al.Cancer. 2012, Vol 118, Num 12, pp 3123-3127, issn 0008-543X, 5 p.Article